Viking Global Investors

Global Processing Services Names Jill Docherty as Director, Global Partnerships

Retrieved on: 
Monday, May 30, 2022
Professional Services, Data Management, Technology, Finance, Software, Banking, Knowledge, API, Business development, Eye, Advent International, Temasek, Low Emission Development Strategies Global Partnership (LEDS GP), Marketing, Mastercard, Visa, GPS, Ecosystem, Adoption, Viking Global Investors, Growth, Financial technology, Customer success, Satellite navigation device, Financial services

Global Processing Services (GPS), a leading global payment technology platform, has today announced the appointment of Jill Docherty as Director, Global Partnerships.

Key Points: 
  • Global Processing Services (GPS), a leading global payment technology platform, has today announced the appointment of Jill Docherty as Director, Global Partnerships.
  • Jill also has extensive international experience having lived and worked across three continents, Africa, Asia-Pacific, and Europe.
  • Joanne Dewar, Chief Executive Officer, GPS, said: We are delighted to welcome Jill to our senior leadership team.
  • Jill Docherty, Director, Global Partnerships, GPS, added: During my fifteen years at Mastercard and Visa I have helped innumerable fintechs launch new card programmes and navigate the payments ecosystem.

Locus Biosciences Announces $35 Million Financing

Retrieved on: 
Wednesday, May 18, 2022
Biomedical Advanced Research and Development Authority, Inflammation, Locus Biosciences, Company, Urinary tract infection, Death, Escherichia coli, Viking Global Investors, Patient, Bacteria, Synthetic biology, CGMP, Medical Hypothesis, Discovery & Innovation in Ophthalmology, COVID-19, RESEARCH, Mortality, Artificial intelligence, PARK, Infection, CRISPR, Virus, Technology, Research Triangle Park, Triangle Park (Quezon City), Tencent, Janssen Pharmaceuticals, AMR, Growth, Development, Genetically modified bacteria, CEO, BARDA, GLOBE, Pharmaceutical industry, Antibiotics, Lancet, Locus

RESEARCH TRIANGLE PARK, N.C., May 18, 2022 (GLOBE NEWSWIRE) -- Locus Biosciences, Inc. (“Locus”), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for a diverse set of bacterial diseases, today announced that it completed a $35 million financing which included a Series B equity financing and conversion of an earlier convertible note. Notable investors participating in the round included Artis Ventures, Tencent Holdings, Viking Global Investors, Johnson and Johnson Innovation – JJDC, Inc. and Discovery Innovations.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., May 18, 2022 (GLOBE NEWSWIRE) -- Locus Biosciences, Inc. (Locus), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for a diverse set of bacterial diseases, today announced that it completed a $35 million financing which included a Series B equity financing and conversion of an earlier convertible note.
  • In addition, funds will support the expansion of Locus discovery platform engine and enhancement of its in-house manufacturing capability to support oral solid dose delivery of its products.
  • This financing helps Locus accelerate our growth, while remaining nimble and adaptable.
  • Locus Biosciences is creating a new class of precision biotherapeutics with clinical-stage, engineered bacteriophage treatments for a diverse set of bacterial and microbiome/inflammatory diseases.

Impossible Foods Launches in the United Kingdom

Retrieved on: 
Wednesday, May 18, 2022
Retail, Restaurant, Bar, Environment, Food, Beverage, People, UBS, Soil, Stanford University, Food, National Restaurant Association, Global Investors Summit, Horizons Ventures, Multimedia, Meat, Impossible Foods, Hungry Horse, Halo Burger, The New York Times, Water, Time, Temasek, Nuggets, GHG, Supermarket, United Kingdom, Restaurant, Impossible, Dairy, Biochemistry, Iron, United Arab Emirates, Taste, Heme, Chicken Cottage, FABI, Howard Hughes Medical Institute, Animal, Friends, GV (company), Viking Global Investors, Khosla Ventures, CEO, Fast food, Plant, Chicken

California-based Impossible Foods, the fastest-growing plant-based meat company in the U.S., is making its European debut in the United Kingdom this week with the launch of two of its latest products Impossible Chicken Nuggets Made From Plants and Impossible Sausage Patties Made From Plants.

Key Points: 
  • California-based Impossible Foods, the fastest-growing plant-based meat company in the U.S., is making its European debut in the United Kingdom this week with the launch of two of its latest products Impossible Chicken Nuggets Made From Plants and Impossible Sausage Patties Made From Plants.
  • Impossible Foods expansion to the UK marks the international debut of Impossible Chicken Nuggets outside of the U.S.
  • To learn more about Impossible Foods launch in the United Kingdom, and to find a participating restaurant near you, please visit www.impossiblefoods.com/gb-en .
  • In addition to the United Kingdom, Impossible Foods products are now available in the U.S., Australia, New Zealand, Canada, Singapore, Hong Kong and the United Arab Emirates.

Dock Raises $110 Million, Bringing Total Valuation to Over $1.5 Billion

Retrieved on: 
Thursday, May 12, 2022
Software, Internet, Finance, Banking, Professional Services, Technology, Mobile, Wireless, Other Technology, API, Allianz Global Investors, Acceleration, Solution, Silver, Technology, Viking Global Investors, Growth, CEO, Online shopping, Dock

With this capital, Dock is one step closer to achieving its mission of democratizing access to financial services for consumers and businesses in Latin America and beyond.

Key Points: 
  • With this capital, Dock is one step closer to achieving its mission of democratizing access to financial services for consumers and businesses in Latin America and beyond.
  • This is only the beginning for us, said Antonio Soares, CEO at Dock.
  • Were excited to partner with Dock to enable greater financial inclusion, which will drive economic growth and increase fairness.
  • 1 Americas Market Intelligence, Card/Payments Processing & Banking-as-a-Service Market Read - Latin America, September 2021
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220512005213/en/

Global Processing Services names Simon Stanford as Chief Revenue Officer

Retrieved on: 
Thursday, May 5, 2022
Professional Services, Data Management, Technology, Finance, Software, Networks, Ecosystem, Advent International, Stanford University, EMEA, Viking Global Investors, Mastercard, Telecommunication, Eye, FX, Â, API, Visa, WeLab Bank, Industry, Starling Bank, Temasek, History, Adoption, Marketing, Worldpay, Samsung Electronics, Growth, GPS, European Conservatives and Reformists Group Executive, Satellite navigation device, Financial services

Global Processing Services (GPS), a leading global payment technology platform, has today announced the appointment of Simon Stanford as Chief Revenue Officer.

Key Points: 
  • Global Processing Services (GPS), a leading global payment technology platform, has today announced the appointment of Simon Stanford as Chief Revenue Officer.
  • Based in London, Stanford sits on GPS global executive committee and leads the companys global commercial, partnerships and customer relationship management, and marketing teams with a focus on developing GPS global partnerships ecosystem, marketing and brand strategy, and driving revenue growth worldwide.
  • Joanne Dewar, Chief Executive Officer, GPS, said: We are delighted to welcome him to our senior leadership team.
  • Global Processing Services (GPS) is the trusted and proven go-to payments processing partner for todays leading fintechs, including Revolut, Curve, Starling Bank, Zilch, WeLab Bank and Paidy.

Cazoo Announces First Quarter 2022 Financial Results

Retrieved on: 
Tuesday, May 3, 2022
Professional Services, Online Retail, Retail, Automotive, General Automotive, Finance, GPU, Communication, Forward-looking statement, Private Securities Litigation Reform Act, NYSE, Form, Viking Global Investors, Disclosure, Allianz Global Investors, Prospectus, Yoy, Business architecture, Intellectual property, Ajax, SEC, Technology, Growth, Awareness, Collection, Online shopping, Cazoo

UK Retail GPU was previously referred to as Retail GPU as we did not have non-UK retail revenues prior to December 2021.

Key Points: 
  • UK Retail GPU was previously referred to as Retail GPU as we did not have non-UK retail revenues prior to December 2021.
  • Investors and analysts interested in participating in the call are invited to dial 1-877-704-6255, or for international callers, 1-215-268-9947.
  • The expectations, estimates, and projections of the business of Cazoo may differ from its actual results and, consequently, you should not rely on forward-looking statements as predictions of future events.
  • You should carefully consider the foregoing factors and the disclosure included in other documents filed by Cazoo from time to time with the SEC.

Chimera Appoints New CEO, Wins AFCR BRACE Award, and Accelerates towards the Clinic with TME-Modifying CAR-T Therapies for Solid Tumors

Retrieved on: 
Thursday, April 28, 2022
Research, Genetics, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Therapeutic index, Viking Global Investors, Program, CEO, Time, Cancer, Biotechnology, Patient, Death, Toxicity, Neoplasm, Harvard Medical School, Pancreas, AFCR, Genetics, Company, Therapy, Data, Science, Breast, GOLD, GSK, Engineering, Amgen, TME, Tumor microenvironment, Lung, Prostate, Hematological Cancer Research Investment and Education Act, Founders Fund, Pharmaceutical industry, Millennium, Chimera, Takeda

Previously, Dr. Hogenhuis was Chief Operating Officer at Ultragenyx Pharmaceuticals and Head of Specialty Pharma and Oncology at GSK.

Key Points: 
  • Previously, Dr. Hogenhuis was Chief Operating Officer at Ultragenyx Pharmaceuticals and Head of Specialty Pharma and Oncology at GSK.
  • CBIO-007 was generated from Chimeras proprietary GOLD Platform technology, which creates conditional, location-specific activation of tumor microenvironment (TME)-modifying payloads by CAR-T cell therapies.
  • Chimera applies its proprietary GOLD Platform to engineer potent CAR-T cell therapies for solid tumors that target the immunosuppressive TME, which has historically limited conventional CAR-T therapeutic efficacy.
  • We believe Chimeras GOLD Platform achieves more control, less toxicity, and greater efficacy for next generation engineered cell therapies.

Elanco and Ginkgo Bioworks Launch BiomEdit, a New Animal Health Company Leveraging Microbiome Technology

Retrieved on: 
Monday, April 11, 2022
Risk, Business development, Ginkgo Bioworks, Soarin' Eagle, Form 10-K, Therapy, Partnership, Leadership, Synthetic biology, Global Investors Summit, Forward-looking statement, K-12, Environmental health, Interpersonal relationship, NYSE, Annual report, Probiotic, SEC, Veterinarian, Livestock, Program, Environment, Biotechnology, PETS, CEO, Health, U.S. Securities and Exchange Commission, Agriculture, COVID-19 testing, LLC, Technology, Intention, Farmer, Securities Exchange Act of 1934, Ecosystem, Securities Act of 1933, Exchange, COVID-19, Suicidal ideation, Intellectual property, Computer, ELAN, Animal, Viking Global Investors, Disease, North American Pet Health Insurance Association, Security (finance), Dietary supplement, Pharmaceutical industry, Antibiotics, Risk management, Ginkgo, Food, Elanco

GREENFIELD, Ind. and BOSTON, April 11, 2022 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN), a leading global animal health company, and Ginkgo Bioworks, the leading horizontal platform for cell programming, today announced the launch of BiomEdit, a microbiome innovation company that is expected to discover, develop and introduce novel probiotics, bioactive molecules, engineered microbial medicines and microbial monitoring services for animal health.

Key Points: 
  • and BOSTON, April 11, 2022 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN), a leading global animal health company, and Ginkgo Bioworks , the leading horizontal platform for cell programming, today announced the launch of BiomEdit, a microbiome innovation company that is expected to discover, develop and introduce novel probiotics, bioactive molecules, engineered microbial medicines and microbial monitoring services for animal health.
  • By leveraging foundational programs from Elanco, intellectual property from both Elanco and Ginkgo, and an experienced team, BiomEdit should be well positioned as a stand-alone company to develop and launch innovative products to address unmet needs in animal health.
  • "Elanco is excited to continue its participation in the microbiome by partnering with Ginkgo, Viking Global Investors and Anterra Capital to create the next-generation animal health innovation player," said Jeff Simmons, president and CEO of Elanco Animal Health.
  • "Together, we see Ginkgo and BiomEdit addressing significant opportunities in the animal health industry with new breakthroughs based on microbiome science.

Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion

Retrieved on: 
Friday, April 1, 2022
Disease, Private Securities Litigation Reform Act, Regulation, Biomarker, LinkedIn, Microfluidics, Transaction, Marketing, Forward-looking statement, Immunotherapy, Viking Global Investors, Growth, Coronavirus, Board, Centerview Partners, Â, Paul, Weiss, Rifkind, Wharton & Garrison, SEC, Biotechnology, Research, Cancer, Health, Failure, U.S. Securities and Exchange Commission, Communication, Jefferies Group, Professional corporation, Government, Quality of life, LLC, CyTOF, Industry, Technology, Director, Twitter, Disclosure, Nasdaq, Wilson Sonsini Goodrich & Rosati, GLOBE, Regulation Fair Disclosure, Eye, SAN, Annual report, FDA, Social media, Security (finance), Renewable energy, Financial adviser, Joseph C. Casdin, Vikings, Fluidigm, Facebook

SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today announced that its stockholders have voted to approve all of the proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC (Casdin) and Viking Global Investors LP (Viking).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today announced that its stockholders have voted to approve all of the proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC (Casdin) and Viking Global Investors LP (Viking).
  • Under the terms of the agreement, Casdin and Viking will purchase $225 million in aggregate principal amount of convertible preferred shares.
  • Jefferies LLC is serving as financial advisor to Fluidigm and Wilson Sonsini Goodrich & Rosati, Professional Corporation is serving as legal advisor.
  • Fluidigm, the Fluidigm logo and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation or its affiliates in the United States and/or other countries.

Global Processing Services Announces New Partnership With Mastercard to Power ‘Next Generation Payments’ Technology to Global Fintechs

Retrieved on: 
Wednesday, March 23, 2022
Technology, Mobile, Wireless, Finance, Security, Professional Services, Software, Networks, Internet, Data Management, Adoption, GPS, Curve, Starling Bank, API, Ecosystem, Mastercard, Time, Advent International, Solution, Eye, Viking Global Investors, Partnership, Financial services, Bank, Temasek

Global Processing Services (GPS), a leading global payment technology platform, today announced a new strategic partnership with Mastercard .

Key Points: 
  • Global Processing Services (GPS), a leading global payment technology platform, today announced a new strategic partnership with Mastercard .
  • Jason Lane, Executive Vice President Market Development Europe, Mastercard, said: We are excited to be formalising our partnership with GPS, working with them to build the fintechs of the future.
  • Joanne Dewar, Chief Executive Officer at GPS, said: Our partnership with Mastercard is a resounding endorsement of our API-first payment technology platform and our bold vision for the future of payments.
  • We welcome them as a GPS investor and we are ready to support many more future Mastercard fintech customers to scale into global businesses with the innovation, speed, and security they expect.